Morgan Stanley upgraded Healthpeak Properties (DOC) to Overweight from Equal Weight with a $25 price target While the firm shares market concerns about elevated lab supply and potential financial pressure on biotech tenants in Healthpeak’s key markets of San Francisco, Boston and San Diego, it also notes their highly occupied and higher quality assets, combined with deep tenant relations, has led them to outperform investor leasing expectation in 2024 and argues this may continue in 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOC:
- Healthpeak Properties price target lowered to $24 from $26 at Evercore ISI
- Healthpeak Properties price target lowered to $23 from $26 at Jefferies
- Healthpeak Properties price target lowered to $22 from $23 at Wells Fargo
- Healthpeak Properties Secures $3 Billion Credit Extension
- Healthpeak Properties price target lowered to $24 from $25 at Mizuho